D. E. Shaw & Co., Inc. Anavex Life Sciences Corp. Call Options Transaction History
D. E. Shaw & Co., Inc.
- $114 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding AVXL
# of Institutions
159Shares Held
31.6MCall Options Held
910KPut Options Held
1.35M-
State Street Corp Boston, MA7.3MShares$30.6 Million0.0% of portfolio
-
Black Rock Inc. New York, NY6.65MShares$27.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.41MShares$18.5 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.71MShares$7.18 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC851KShares$3.57 Million0.0% of portfolio
About ANAVEX LIFE SCIENCES CORP.
- Ticker AVXL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,942,800
- Market Cap $327M
- Description
- Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...